The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor, entinostat, in patients with metastatic renal cell carcinoma: Safety and tolerability results.
Roberto Pili
No relevant relationships to disclose
Li Shen
No relevant relationships to disclose
Saby George
No relevant relationships to disclose
Hans J. Hammers
No relevant relationships to disclose
Anita Sandecki
No relevant relationships to disclose
Connie Collins
No relevant relationships to disclose
Michael Anthony Carducci
No relevant relationships to disclose